3IP
VRTX icon

3Chopt Investment Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

3Chopt Investment Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.75M Sell
3,522
-173
-5% -$76.7K 0.33% 65
2026
Q1 		$1.65M Sell
3,695
-491
-12% -$229K 0.38% 59
2025
Q4 		$1.9M Sell
4,186
-247
-6% -$106K 0.43% 58
2025
Q3 		$1.74M Sell
4,433
-479
-10% -$200K 0.4% 61
2025
Q2 		$2.19M Sell
4,912
-367
-7% -$169K 0.53% 48
2025
Q1 		$2.56M Sell
5,279
-442
-8% -$206K 0.67% 38
2024
Q4 		$2.3M Sell
5,721
-1,316
-19% -$610K 0.79% 41
2024
Q3 		$3.27M Sell
7,037
-905
-11% -$435K 1.17% 25
2024
Q2 		$3.72M Buy
7,942
+122
+2% +$53K 1.14% 14
2024
Q1 		$3.27M Buy
7,820
+1,033
+15% +$437K 1.34% 18
2023
Q4 		$2.76M Buy
6,787
+856
+14% +$316K 1.02% 20
2023
Q3 		$2.06M Buy
5,931
+112
+2% +$39.2K 1.22% 31
2023
Q2 		$2.05M Sell
5,819
-276
-5% -$93K 1.02% 32
2023
Q1 		$1.92M Buy
6,095
+493
+9% +$148K 1.02% 31
2022
Q4 		$1.62M Buy
+5,602
New +$1.71M 0.88% 38

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

3Chopt Investment Partners's VRTX Position: Q2 2026 in Review

3Chopt Investment Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 4.7% in Q2 2026, selling an estimated $76.7K and leaving 3,522 shares worth $1.75M. The position accounts for 0.33% of the portfolio, ranked #65.

3Chopt Investment Partners first reported a position in VRTX in Q4 2022 and has held it in 15 quarters since. The position peaked at $3.72M in Q2 2024. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • 3Chopt Investment Partners held 3,522 shares of Vertex Pharmaceuticals worth $1.75M as of Q2 2026.
  • 3Chopt Investment Partners sold 173 Vertex Pharmaceuticals shares in Q2 2026, an estimated $76.7K.
  • Vertex Pharmaceuticals made up 0.33% of 3Chopt Investment Partners's portfolio in Q2 2026, its #65 holding.
  • 3Chopt Investment Partners first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • 3Chopt Investment Partners's Vertex Pharmaceuticals position peaked at $3.72M in Q2 2024.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on 3Chopt Investment Partners's 13F filing for Q2 2026, filed 29 Jul 2026.